ASH 2022 Conference Coverage
N

ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM Patients

By ASH 2022 Conference Coverage FEATURING Neha Korde
December 21, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

14:48
Seagen

Impact on the Future of First Line Treatment in Stage III/IV Classic…

Feat. A. Forman

Featured Video

17:12
Seagen

Strategies for Managing Toxicities Associated with a First Line Trea…

Feat. A. Forman

Related Content

AUTOPLAY
26:57
Saad Usmani

Immune Approaches and Targeted Therapies for Myeloma: The Future

11:56
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Myeloma Highlights: Genetic Engineering of T-cells, Dara-VM…

Feat. A. Rosko
15:23
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Frontline MM for Older Adults: Does Biologic…

Feat. B. Lipe
03:34
Krina Patel

The Future in Multiple Myeloma: BiTE, CAR T, PI, & IMID

21:58
Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

Treatment of 57 y/o Women with Myeloma R-ISS Stage 1, Anemia and Lyt…

Feat. A. Cohen, D. Vogl, A. Garfall
14:12
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Myeloma Bone Disease and Management: Optimal Imaging Supports Clinic…

Feat. M. Drake
15:54
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MRD in Newly Diagnosed MM: MRI vs. PET/CT, RVD+/-ASCT, Dara+Len to R…

Feat. E. Terpos
08:48
SOHO 4th Italian Conference

SOHO Italy 2022: Therapy-Related Myeloid Neoplasm After Multiple Mye…

Feat. L. Cicconi
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and M…

13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

15:09
2nd SOHO Italian Conference

How I Treat Unfit/Frail MM Patients: Is Frailty Measurable and Do No…

Feat. D. Derudas
13:22
SOHO 3rd Italian Conference

SOHO Italy 2021 on the Importance of Imaging in Novel Agents' E…

Feat. E. Zamagni
33:59
Roswell Park Comprehensive Cancer Center

Minimal Residual Disease (MRD) Testing in Multiple Myeloma. How and …

Feat. P. McCarthy
07:22
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Multiple Myeloma: What Are the Response Rate…

Feat. R. Redner
11:56
Indy Hematology Review

Initial and Maintence Therapy for Multiple Myeloma

Feat. K. Anderson
09:46
SOHO 3rd Italian Conference

SOHO Italy 2021 on MM Prognostication and Optimal Upfront Drug Selec…

Feat. M. Sonia González Pérez
07:11
8th Eurasian Hematology Oncology Summit

Survival Data for Newly Diagnosed ASCT-Ineligible MM: VRd vs. Rd, VM…

Feat. A. Maiolino
13:57
SOHO 3rd Italian Conference

SOHO Italy 2021 Update on ADCs, Bispecific, and Trispecific Antibodi…

Feat. H. Lee
09:45
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Newly Diagnosed MM: How Does Daratumumab + R…

Feat. A. Nooka
11:50
Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

Transplant and Maintenance in Frontline Multiple Myeloma: High-dose …

Feat. A. Garfall